14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
INCY vs VRTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Vertex Pharmaceuticals Inc (VRTX) is the stronger overall head-to-head candidate over Incyte Genomics Inc (INCY) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). INCY carries a Unified Composite Score of 61.2/100 (BUY) at $120.55 (14.0x Forward P/E, 32.2% operating margin), whereas VRTX carries 37.0/100 (SELL) at $536.61 (27.0x Forward P/E, 37.8% operating margin).
Composite vs. Pillar Nuance: While INCY currently prints a higher short-term Unified Composite Score (61.2/100 BUY vs. VRTX 37.0/100 SELL), VRTX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (37.8% vs. 32.2% operating margin) and revenue trajectory (+11.8% vs. +14.0% YoY).
Competes within the Biotechnology value chain with $24.8B market capitalization and 32.2% operating margin.
OpEx & R&D Reinvestment23.8% of Rev ($1.43B)
90D Engineering Disclosures0 Published
VRTX Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $137.6B market capitalization and 37.8% operating margin.
OpEx & R&D Reinvestment17.0% of Rev ($2.20B)
90D Engineering Disclosures0 Published
Investor FAQ INCY vs VRTX Key Questions & Quantitative Answers
As of Nov 16, 2026, Vertex Pharmaceuticals Inc (VRTX) is the stronger overall head-to-head candidate over Incyte Genomics Inc (INCY) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). INCY carries a Unified Composite Score of 61.2/100 (BUY) at $120.55 (14.0x Forward P/E, 32.2% operating margin), whereas VRTX carries 37.0/100 (SELL) at $536.61 (27.0x Forward P/E, 37.8% operating margin). Composite vs. Pillar Nuance: While INCY currently prints a higher short-term Unified Composite Score (61.2/100 BUY vs. VRTX 37.0/100 SELL), VRTX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (37.8% vs. 32.2% operating margin) and revenue trajectory (+11.8% vs. +14.0% YoY).
INCY leads the Growth & Scale pillar: INCY posts +14.0% YoY revenue growth and +37.7% YoY earnings growth on $6.01B TTM revenue (56.0% gross margin, 32.2% operating margin), compared with VRTX at +11.8% YoY revenue growth and -39.0% YoY earnings growth on $13.0B TTM revenue (54.8% gross margin, 37.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), INCY cumulative revenue shifted +173.4% while VRTX shifted +293.4%. In operating R&D and SG&A reinvestment, INCY deploys 23.8% of Rev ($1.43B) (0 90-day corporate R&D disclosures) versus 17.0% of Rev ($2.20B) (0 disclosures) for VRTX.
INCY screens cheaper on headline valuation multiples. INCY trades at 14.0x Forward P/E, 62.1x Trailing P/E, 10.82x PEG, and 3.6x EV/Revenue (11.3% FCF margin), whereas VRTX trades at 27.0x Forward P/E, 34.9x Trailing P/E, 2.38x PEG, and 10.7x EV/Revenue (24.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INCY (7.8% ROE) versus VRTX (20.8% ROE) capital efficiency.
In options market volatility and institutional positioning, INCY carries 36.5% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 35% Vol realized risk). By comparison, VRTX carries 88.3% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 1.42x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.36β · 30% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.